Novo Nordisk A/S
NOVO-B
Classificação em ações
#106
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Preço da ação
$39.47
Valor de mercado
$174.18B
Variação (1 dia)
0.59%
Variação (1 ano)
-26.09%
País
DK
Negociar Novo Nordisk A/S (NOVO-B)
Categoria
Healthcare
Lucros da Novo Nordisk A/S (NOVO-B)
Lucros em Dec 2025 TTM: $20.51B
De acordo com os últimos relatórios financeiros da Novo Nordisk A/S, os ganhos atuais da empresa são de $20.51B. Em 2024, a empresa teve ganhos de $17.75B, um aumento em relação a aos ganhos de 2023, que foram de $15.50B. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Novo Nordisk A/S de 2001 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $20.51B | 0.00% |
| 2025 | $20.51B | 15.55% |
| 2024 | $17.75B | 14.50% |
| 2023 | $15.50B | 55.92% |
| 2022 | $9.94B | 10.02% |
| 2021 | $9.03B | 3.59% |
| 2020 | $8.72B | 19.69% |
| 2019 | $7.29B | -0.35% |
| 2018 | $7.31B | -6.79% |
| 2017 | $7.84B | 15.64% |
| 2016 | $6.78B | 7.06% |
| 2015 | $6.34B | 14.26% |
| 2014 | $5.55B | -7.59% |
| 2013 | $6.00B | 22.00% |
| 2012 | $4.92B | 28.80% |
| 2011 | $3.82B | 16.43% |
| 2010 | $3.28B | 21.42% |
| 2009 | $2.70B | 13.54% |
| 2008 | $2.38B | 10.14% |
| 2007 | $2.16B | 33.54% |
| 2006 | $1.62B | 24.30% |
| 2005 | $1.30B | -5.19% |
| 2004 | $1.37B | 6.85% |
| 2003 | $1.28B | 44.62% |
| 2002 | $888.11M | 23.73% |
| 2001 | $717.79M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $33.60B | 63.84% |
US
|
|
| $17.74B | -13.50% |
US
|
|
| $8.70B | -57.58% |
US
|
|
| $5.95B | -70.99% |
US
|
|
| $21.39B | 4.31% |
CH
|
